42 Chabala C, Turkova A, Hesseling AC, et al. Pharmacokinetics of first-line drugs in children with tuberculosis, using World Health Organization-recommended weight band doses and formulations. Clin Infect Dis 2022 74: 1767–1775. 43 Jacobs TG, Svensson EM, Musiime V, et al. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. J Antimicrob Chemother 2020 75: 3433–3457. 44 Chiang SS, Khan FA, Milstein MB, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2014 14: 947–957. 45 Huynh J, Abo YN, du Preez K, et al. Tuberculous meningitis in children: reducing the burden of death and disability. Pathogens 2021 11: 38. 46 Seddon JA, Tugume L, Solomons R, et al. The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res 2019 4: 167. 47 Svensson EM, Dian S, Te Brake L, et al. Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials. Clin Infect Dis 2020 71: 1817–1823. 48 Paradkar MS, Devaleenal D B, Mvalo T, et al. Randomized clinical trial of high-dose rifampicin with or without levofloxacin versus standard of care for pediatric tuberculous meningitis: the TBM-KIDS trial. Clin Infect Dis 2022 75: 1594–1601. 49 Garcia-Prats AJ, Svensson EM, Winckler J, et al. Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. J Antimicrob Chemother 2021 76: 3237–3246. 50 WHO. WHO Statement on the Use of Child-friendly Fixed-dose Combinations for the Treatment of TB in Children. Geneva, WHO, 2017. 51 Solomons RS, van Toorn R, Cresswell FV, et al. Update on the treatment of pediatric tuberculous meningitis. Pediatr Infect Dis J 2022 41: e393–e395. 52 Schoeman J, Mansvelt E, Springer P, et al. Coagulant and fibrinolytic status in tuberculous meningitis. Pediatr Infect Dis J 2007 26: 428–431. 53 Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci 2010 293: 12–17. 54 Nyang’wa BT, Berry C, Kazounis E, et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med 2022 387: 2331–2343. 55 Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Management of Drug-Resistant Tuberculosis in Children: A Field Guide. 5th Edn. Boston, Sentinel Project for Pediatric Drug-Resistant Tuberculosis, 2021. 56 Patankar S, Cruz AT, Douglas-Jones B, et al. Making the case for all-oral, shorter regimens for children with drug-resistant tuberculosis. Am J Respir Crit Care Med 2023 208: 130–131. 57 Garcia-Prats AJ, Hoddinott G, Howell P, et al. Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis. Lancet Infect Dis 2023 23: 778–780. 58 WHO. WHO Operational Handbook on Tuberculosis: Module 4: Treatment – Drug-resistant Tuberculosis Treatment, 2022 Update. Geneva, WHO, 2022. 59 Howell P, Achar J, Huang GKL, et al. Treatment of rifampicin-resistant tuberculosis disease and infection in children: key updates, challenges and opportunities. Pathogens 2022 11: 381. 60 Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep 2011 3: e16. 61 Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review. Trop Med Int Health 2009 14: 1329–1337. 62 Li Y, Zhu Y, Zhong Q, et al. Serious adverse reactions from anti-tuberculosis drugs among 599 children hospitalized for tuberculosis. Pediatr Infect Dis J 2017 36: 720–725. 63 Turkova A, Waalewijn H, Chan MK, et al. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Lancet HIV 2022 9: e627–e637. 64 Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med 2018 15: e1002591. 65 Alipanah N, Jarlsberg L, Miller C, et al. Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. PLoS Med 2018 15: e1002595. 66 WHO. Meeting Report of the WHO Expert Consultation on Drug-resistant Tuberculosis Treatment Outcome Definitions. Geneva, WHO, 2020. 67 Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines. Antimicrob Agents Chemother 2016 60: 2171–2179. 68 Daskapan A, Idrus LR, Postma MJ, et al. A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs. Clin Pharmacokinet 2019 58: 747–766. 69 Ramachandran G, Kumar AKH, Kannan T, et al. Low serum concentrations of rifampicin and pyrazinamide associated with poor treatment outcomes in children with tuberculosis related to HIV status. Pediatr Infect Dis J 2016 35: 530–534. https://doi.org/10.1183/2312508X.10025322 233 CHILDREN AND ADOLESCENTS |E. LÓPEZ-VARELA ET AL.